The content on this site is intended for healthcare professionals only
Dr Philippe Moreau speaks with ecancertv at BSH 2016 about his research into novel therapies to treat myeloma.
Following recent approval in the USA and favourable views in the CHMP, Dr Moreau looks forward to the improved patient outlook possible with courses of elotuzumab or daratumumab.
As combination therapies, elotuzumab and daratumumab have shown significant benefits to patient duration, progression free survival and toxicity profile.
With an eye to the future, he looks forward to novel combinations to maximise patient benefit, up to complete remission.
ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Molecular profiling in prostate cancer: key challenges for clinical implementation
